Skip to main content
D

Dewcell

This biotechnology company develops artificial platelets through human-derived stem cell-induced differentiation into megakaryocytes, utilizing biomimetic technology for mass production. Their solution addresses the critical shortage of blood-derived platelets, providing a reliable alternative for medical applications.

성남시, 대한민국
Updated 2 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

The supply of blood-derived platelets is often insufficient to meet clinical needs due to a limited donor base and challenges in storage and transportation. This shortage can lead to delays in critical medical procedures and compromise patient care, especially for individuals with thrombocytopenia or undergoing intensive treatments.

Solution

Dewcell is developing artificial platelets derived from human stem cells through induced differentiation into megakaryocytes, addressing the critical shortage of blood-derived platelets. By leveraging biomimetic technology, Dewcell aims to mass-produce functional, artificial platelets that can reliably supplement or replace donor platelets in various medical applications. Their engineered artificial platelets (en-aPLT™) and induced pluripotent stem cell (iPSC)-derived artificial platelet-like particles (i-aPLP™) are designed to mimic the natural function of platelets in hemostasis and thrombosis. Dewcell's technology aims to establish a consistent and scalable production system, ensuring a stable supply of platelets with thorough quality control.

Target Audience

The primary target audience includes hospitals, blood banks, and research institutions that require a reliable and scalable source of platelets for transfusions, research, and drug development.

Features

  • en-aPLT™: Engineered artificial platelets derived from stem cells.
  • i-aPLP™: iPSC-derived artificial platelet-like particles.
  • i-ahPLys™: iPSC-derived artificial human platelet lysate
  • Biomimetic approach to replicate the structure and function of natural platelets.
  • Scalable manufacturing process for mass production.
  • Strict quality control measures throughout the production process.
This profile is AI-generated and may contain inaccuracies.